Ebola medical therapy

Revision as of 15:25, 5 April 2012 by Michael Maddaleni (talk | contribs) (Created page with "{{Ebola}} {{CMG}} ==Overview== frame|right|A hospital isolation ward in [[Gulu, Uganda during the October 2000 out...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Ebola Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ebola from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Algorithm for the Evaluation of the Returned Traveler

Emergency Department Evaluation

Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Hospital Preparedness

Checklists

Air Medical Transport

Monitoring and Movement Following Exposure

Primary Prevention

Future or Investigational Therapies

Postmortem Care

Postmortem Care

Case Studies

Case #1

Ebola medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ebola medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ebola medical therapy

CDC on Ebola medical therapy

Ebola medical therapy in the news

Blogs on Ebola medical therapy

Directions to Hospitals Treating ebola

Risk calculators and risk factors for Ebola medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

A hospital isolation ward in Gulu, Uganda during the October 2000 outbreak

Treatment is primarily supportive and includes:

  • Minimizing invasive procedures
  • Balancing electrolytes since patients are frequently dehydrated
  • Replacing lost coagulation factors to help stop bleeding
  • Maintaining oxygen and blood levels
  • Treating any complicating infections.

Convalescent Plasma (factors from those who have survived Ebola infection) shows promise as a treatment for the disease. Ribavirin is ineffective. Interferon is also thought to be ineffective. In monkeys, administration of an inhibitor of coagulation (rNAPc2) has shown some benefit, protecting 33% of infected animals from a usually 100% (for monkeys) lethal infection (unfortunately this inoculation does not work on humans). In early 2006, scientists at USAMRIID announced a 75% recovery rate after infecting four rhesus monkeys with Ebola virus and administering antisense drugs.[1]

References

  1. "USAMRIID press release" (PDF) (Press release).